The Q&A with Tom Klima of bluebird bio highlights the company’s achievements in gene therapy, particularly with its three FDA-approved treatments for β-thalassemia, cerebral adrenoleukodystrophy (CALD), and sickle cell disease. Klima discusses bluebird’s transition from research to commercialization, their commitment to patient-centered therapies, and the challenges in manufacturing gene therapies. Located in Somerville, bluebird bio values Massachusetts’ biotech ecosystem for advancing gene therapies and scaling production. Their focus remains on expanding access to these innovative treatments.

Read more here.